RLMD earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -4.50. Updated 2026-07-23.
Relmada Therapeutics (RLMD) Research Hub
Relmada Therapeutics (RLMD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.23 USD (-1.22%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.50, market cap 0.52B. This hub links to the full technical, earnings and options research available for RLMD.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.23 USD (-1.22%) |
| 52-week range | 3.075 USD – 7.12 USD |
| Trend regime | Range |
| 14-day RSI | 48.2 (Neutral) |
| Trailing P/E | -4.50 |
| Market cap | 0.52B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for RLMD
Covered Call on RLMD: how it works, illustrative setup around the real 3.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RLMD: how it works, illustrative setup around the real 3.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RLMD: how it works, illustrative setup around the real 3.23 USD price, max profit/loss, breakeven and when to use it. Educational.
RLMD technical analysis: range, last 3.23 USD, RSI 48.2, 52w range 3.075 USD–7.12 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RLMD in?
Relmada Therapeutics (RLMD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RLMD in an uptrend or downtrend?
As of 2026-10-26, RLMD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RLMD's trailing P/E ratio?
RLMD's trailing P/E is -4.50, with a market cap of 0.52B. See the earnings research page for full valuation detail.
When does RLMD next report earnings?
RLMD is next scheduled to report earnings on 2026-08-06.